Arvinas's second quarter is two different reports stapled together, and only one of them is about the biotech. The first is the FDA's approval of VEPPANU, the first-ever green light for a PROTAC protein degrader, in late second-quarter 2026 - a regulatory first for the entire protein-degradation modality. The second is a single transaction: Arvinas and Pfizer sold the global rights to that same approved drug to Rigel Pharmaceuticals for $70 million upfront, with another $15 million on transition, up to $320 million in milestones, and tiered royalties in the mid-teens to mid-20s on worldwide net sales. The Rigel deal cleared out $179.1 million of deferred revenue on the books in one stroke, and Arvinas recorded GAAP net income of $169.4 million for the quarter - versus a $61.2 million loss a year ago - on revenue of $249.7 million (up from $22.4 million). That is the number that makes a market stop scrolling.
The other number is the one that should. Cash, cash equivalents and marketable securities stood at $567.9 million at June 30, 2026, and management says the runway stretches into the second half of 2028 - funding multiple Phase 1 readouts across Arvinas's wholly-owned pipeline (ARV-393, ARV-102, ARV-027 and ARV-806) without another financing round. The first half of 2026, however, used $117.5 million of operating cash - and that was a quarter before ARV-393 dose-escalation data, before the ARV-102 PSP program resolved its FDA hold, before ARV-806 dose-escalation read out, and before a new chief medical officer is even seated. The second half is more expensive than the first half, on the operating-cost line, and the cash clock is now the load-bearing number. The Rigel deal was the financing; the pipeline is the spend. The thesis is that four PROTAC Phase 1 readouts can run on $568 million of cash. The risk is that they can't.
The accounting produces its own contradictions. Excluding the Rigel-driven deferred-revenue release, the underlying research and development spend was $52.6 million in the quarter (down from $68.6 million a year ago on the post-restructuring cost base) and general and administrative was $24.0 million (versus $25.3 million). The "ex-items" quarter is small and quiet: an early-clinical biotech in cost-cut mode, with no product revenue of its own, dependent on partner milestones. GAAP diluted EPS of $2.58 is a contract-modification print, not a P&L. The same Q2 result that delivers a $169.4 million profit on the income statement produces an operating cash use of roughly $50 million (recovered by differencing the H1 OCF). The market is being asked to value the platform on a deferred-revenue release and a royalty stream from an asset Arvinas no longer controls, against a Phase 1 pipeline that needs three to four years of data to anchor a re-rating. The cash is the floor. The readouts are the ceiling. The price is the spread.